Page 140 - Read Online

5. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter 25. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and
I, Chitnis T; GJCF International Clinical Consortium & Biorepository safety of mitoxantrone in patients with highly relapsing neuromyelitis
for Neuromyelitis Optica. Demographic and clinical features of optica. Arch Neurol 2011;68:473-9.
neuromyelitis optica: a review. Mult Scler 2015;21:845-53. 26. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob
6. Flanagan EP, Cabre P, Weinshenker BG, St Sauver J, Jacobson A, Leite MI, Palace J. Methotrexate is an alternative to azathioprine
DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, in neuromyelitis optica spectrum disorders with aquaporin-4
Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Borders antibodies. J Neurol Neurosurg Psychiatry 2013; 84:918-21.
Robinson A, Pittock SJ. Epidemiology of aquaporin-4 autoimmunity 27. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K,
and neuromyelitis optica spectrum. Ann Neurol 2016; doi: 10.1002/ Itoyama Y. Low-dose corticosteroids reduce relapses in neuromyelitis
ana.24617. optica: a retrospective analysis. Mult Scler 2007;13:968-74.
7. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis 28. Rossi D, Modena V, Sciascia S, Roccatello D. Rheumatoid arthritis:
C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, biological therapy other than anti-TNF. Int Immunopharmacol
Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, 2015;27:185-8.
Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss 29. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An
JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy open label study of the effects of rituximab in neuromyelitis optica.
U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh Neurology 2005;64:1270-2.
FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, 30. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of
Munch C, Winkelmann A, Zettl UU, Metz I, Veauthier C, Sieb JP, rituximab treatment in patients with neuromyelitis optica spectrum
Wilke C, Hartung HP, Aktas O, Paul F. Contrasting disease patterns disorder. JAMA Neurol 2013;70:1110-7.
in seropositive and seronegative neuromyelitis optica: a multicentre 31. Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhangning
study of 175 patients. J Neuroinflammation 2012;9:14. N, Liu Q, Shao ZH, Yu C, Shi FD. Responsiveness to reduced
8. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, dosage of rituximab in Chinese patients with neuromyelitis optica.
Weinshenker BG. Revised diagnostic criteria for neuromyelitis Neurology 2013;81:710-3.
optica. Neurology 2006;66:1485-9. 32. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG,
9. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Lucchinetti CF, O’Toole O, Wingerchuk DM. Eculizumab in AQP4-
Weinshenker BG. The spectrum of neuromyelitis optica. Lancet IgG-positive relapsing neuromyelitis optica spectrum disorders: an
Neurol 2007;6:805-15. open-label pilot study. Lancet Neurol 2013;12:554-62.
10. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, 33. Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A,
Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Tradtrantip L, Verkman AS. C1q-targeted monoclonal antibody
Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee prevents complement-dependent cytotoxicity and neuropathology
AL, Waters P, Wellik KE, Weinshenker BG; International in in vitro and mouse models of neuromyelitis optica. Acta
Panel for NMO Diagnosis. International consensus diagnostic Neuropathol 2013;125:829-40.
criteria for neuromyelitis optica spectrum disorders. Neurology 34. Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe
2015;85:177-89. in acute relapses of neuromyelitis optica. Neurol Neuroimmunol
11. Agre P, Kozono D. Aquaporin water channels: molecular Neuroinflamm 2014;1:e5.
mechanisms for human diseases. FEBS Lett 2003;555:72-8. 35. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T,
12. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes
optica. Lancet Neurol 2012;11:535-44. anti-aquaporin 4 autoantibody production from plasmablasts in
13. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, neuromyelitis optica. Proc Natl Acad Sci U S A 2011;108:3701-6.
Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in 36. Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, Ito S,
neuromyelitis optica exhibit a Th17 bias and recognize Clostridium Nomura F, Kuwabara S. Cerebrospinal fluid interleukin-6 and
ABC transporter. Ann Neurol 2012;72:53-64. glial fibrillary acidic protein levels are increased during initial
14. Koga M, Takahashi T, Kawai M, Fujihara K, Kanda T. A neuromyelitis optica attacks. Clin Chim Acta 2013 5;421:181-3.
serological analysis of viral and bacterial infections associated with 37. Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S,
neuromyelitis optica. J Neurol Sci 2011;300:19-22. Kuwabara S. Markedly increased CSF interleukin-6 levels in
15. Li YJ, Zhang F, Qi Y, Chang GQ, Fu Y, Su L, Shen Y, Sun N, Borazanci neuromyelitis optica, but not in multiple sclerosis. J Neurol
A, Yang C, Shi FD, Yan Y. Association of circulating follicular 2009;256:2082-4.
helper T cells with disease course of NMO spectrum disorders. J 38. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S,
Neuroimmunol 2015;278:239-46. Yamamura T. Clinical improvement in a patient with neuromyelitis
16. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol optica following therapy with the anti-IL-6 receptor monoclonal
2006;533:2-14. antibody tocilizumab. Mod Rheumatol 2013;23:827-31.
17. Bienia B, Balabanov R. Immunotherapy of neuromyelitis optica. 39. Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg
Autoimmune Dis 2013;2013:741490. AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP.
18. Bonnan M, Cabre P. Plasma exchange in severe attacks of Disease amelioration with tocilizumab in a treatment-resistant
neuromyelitis optica. Mult Scler Int 2012;2012:787630. patient with neuromyelitis optica: implication for cellular immune
19. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. responses. JAMA Neurol 2013;70:390-3.
Role of intravenous immunoglobulin in the treatment of acute 40. Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura
relapses of neuromyelitis optica: experience in 10 patients. Mult T, Gold R. Interleukin 6 receptor blockade in patients with
Scler 2014;20:501-4. neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA
20. Okada K, Tsuji S, Tanaka K. Intermittent intravenous Neurol 2013;70:394-7.
immunoglobulin successfully prevents relapses of neuromyelitis 41. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M,
optica. Intern Med 2007;46:1671-2. Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer
21. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W,
SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, Wildemann B. Cerebrospinal fluid findings in aquaporin-4 antibody
efficacy, and predictors of benefit in neuromyelitis optica. Neurology positive neuromyelitis optica: results from 211 lumbar punctures. J
2011;77:659-66. Neurol Sci 2011;306:82-90.
22. Qiu W, Kermode AG, Li R, Dai Y, Wang Y, Wang J, Zhong X, Li C, 42. Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, Kanda
Lu Z, Hu X. Azathioprine plus corticosteroid treatment in Chinese T. Sera from neuromyelitis optica patients disrupt the blood-brain
patients with neuromyelitis optica. J Cli Neurosci 2015;22:1178-82. barrier. J Neurol Neurosurg Psychiatry 2012;83:288-97.
23. Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, Kim 43. Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, Antel
HJ. Mycophenolate mofetil in the treatment of neuromyelitis optica JP. Functional consequences of neuromyelitis optica-IgG astrocyte
spectrum disorder. JAMA Neuro 2014;l71:1372-8. interactions on blood-brain barrier permeability and granulocyte
24. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, recruitment. J immunol 2008;181:5730-7.
Sharma J, Feichter J, Bakshi R. Study of mitoxantrone for the 44. Tasaki A, Shimizu F, Sano Y, Fujisawa M, Takahashi T, Haruki H,
treatment of recurrent neuromyelitis optica (Devic disease). Arch Abe M, Koga M, Kanda T. Autocrine MMP-2/9 secretion increases
Neurol 2003;63:957-63. the BBB permeability in neuromyelitis optica. J Neurol Neurosurg

Neuroimmunol Neuroinflammation | Volume 3 | June 20, 2016 131